ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1886

Measuring Physical Activity in AxSpA:Content Validity and Measurement Properties of the New AxSpA-SQUASH

Marllies Carbo1, Davy Paap2, Fiona Maas1, Mark Siderius3, Hendrika Bootsma1, Freke Wink3, Suzanne Arends3 and Anneke Spoorenberg3, 1University Medical Centre Groningen, Groningen, Netherlands, 2, Department of Rehabilitation Medicine, University of Medical Centre Groningen, Groningen, Netherlands, 3University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands

Meeting: ACR Convergence 2020

Keywords: Measurement Instrument, OMERACT, physical activity, Spondylarthropathies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: The ASAS-EULAR recommendations for management of axial Spondyloarthritis (axSpA) includes that patients should be encouraged to exercise. There is no validated instrument for measuring physical activity in axSpA. Our previous study recommends to adapt the Short QUestionnaire to Assess Health-enhancing physical activity (SQUASH) to improve the validity in axSpA patients. Our goal was to mak an AxSpA-disease specific adaptation of the physical activity questionnaire SQUASH to improve content validity and measurement properties.

Methods: This study was conducted according to the OMERACT-filter within the Groningen Leeuwarden AxSpA (GLAS) cohort and was performed in two parts. Part 1: adaptation and evaluation of content validity using a qualitative stepwise approach with in-depth interviews with different healthcare professionals (n=9) and patients (n=8), field testing in patients (n=10), and consensus meeting for final adaptations. Thereafter, content validity (n=45) was tested by filling out axSpA-SQUASH and SQUASH in random order two weeks apart. Part 2: measurement properties were tested using the International Physical Activity Questionnaire (IPAQ) as comparator. Criterion validity (n=40): Spearman’s correlation with accelerometer as golden standard and classification accuracy of intensity. Construct validity (n=106): Spearman’s correlation with disease activity, physical functioning and quality of life as clinical outcome with expected fair to moderated associations. Test-retest reliability (n=45): intraclass correlation coefficients (ICC) after 2 weeks. Responsiveness (n=47): standardized response mean (SRM) after 3 months stratified by Ancor method.

Results: In total 156 patients were included: mean age 48±13 years, 56% males, 72% HLA-B27 positive, symptom duration 21±13.3 years and ASDAS 2.0±1.0. Part 1: main adaptations were better explanation of intensities, adding answer option “not applicable”, examples were modernized, physiotherapy and activity “shopping” were added. Compared to the original SQUASH, the adapted axSpA-SQUASH measured a systematically higher activity count and had less missing values (8% vs. 32%). Part 2: criterion validity: axSpA-SQUASH correlated better with accelerometer compared to IPAQ (ρ=0.51 vs. ρ=0.35). Classification accuracy: accelerometer defined most activity as light (97%), whereas axSpA-SQUASH and IPAQ defined most activity as moderate intensity (55% and 62% resp.). Construct validity: correlations were low to moderate and strongest for axSpA-SQUASH compared to IPAQ. Construct validity: correlations were low to moderate and stronger for axSpA-SQUASH compared to IPAQ (BASDAI -0.27 vs -0.15, BASDAI –0.27 vs. -0.15, ASDAS -0.24 vs -0.09, BASFI -0.39vs. -0.21, ASQoL -0.39 vs. -0.35). Test-retest reliability: ICC axSpA-SQUASH: 0.80. Responsiveness: axSpA-SQUASH changed over time in the corresponding direction (Table 1). Feasibility: considered comprehensible and average completion time was 7 minutes.

Conclusion: The new axSpA-SQUASH resulted in improved content validity and measurement properties. It  seems the most appropriate questionnaire and can be used to assess daily physical activity in patients with axSpA.

Table 1. Responsiveness of the axSpA-SQUASH versus change in BASDAI


Disclosure: M. Carbo, None; D. Paap, None; F. Maas, None; M. Siderius, None; H. Bootsma, Bristol-Myers Squibb, 2, 5, 8, Roche, 2, 5, Novartis, 5, 8, Medimmune, 5, Union Chimique Belge, 5; F. Wink, Abbvie, 5, Janssen, 5; S. Arends, Pfizer, 2; A. Spoorenberg, Pfizer, 1, 2, Novartis, 1, 2, Abbvie pharmaceuticals, 1, 2, MSD, 1, UCB, 1.

To cite this abstract in AMA style:

Carbo M, Paap D, Maas F, Siderius M, Bootsma H, Wink F, Arends S, Spoorenberg A. Measuring Physical Activity in AxSpA:Content Validity and Measurement Properties of the New AxSpA-SQUASH [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/measuring-physical-activity-in-axspacontent-validity-and-measurement-properties-of-the-new-axspa-squash/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/measuring-physical-activity-in-axspacontent-validity-and-measurement-properties-of-the-new-axspa-squash/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology